文章名稱引用次數(shù)

• Global, regional, and national incidence, prevalence, and mortality of HIV, 1980- and forecasts to for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 201747
• Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-1737
• Barriers and strategies to achieve a cure for HIV24
• Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study21
• Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study19
• Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase non-inferiority trial19
• Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase non-inferiority trial18
• Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial17
• Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase non-inferiority trial15
• Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies15